[go: up one dir, main page]

SV2004001674A - Conjugacion y proceso para la preparacion de una hormona monopegilatada terminalmente-n para una hormona para el crecimiento humano ref. 01449/1 - Google Patents

Conjugacion y proceso para la preparacion de una hormona monopegilatada terminalmente-n para una hormona para el crecimiento humano ref. 01449/1

Info

Publication number
SV2004001674A
SV2004001674A SV2003001674A SV2003001674A SV2004001674A SV 2004001674 A SV2004001674 A SV 2004001674A SV 2003001674 A SV2003001674 A SV 2003001674A SV 2003001674 A SV2003001674 A SV 2003001674A SV 2004001674 A SV2004001674 A SV 2004001674A
Authority
SV
El Salvador
Prior art keywords
hormone
monopegilated
terminally
conjugation
ref
Prior art date
Application number
SV2003001674A
Other languages
English (en)
Inventor
Rory F Finn
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of SV2004001674A publication Critical patent/SV2004001674A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE ENCUENTRA EN INGLES
SV2003001674A 2002-11-20 2003-11-20 Conjugacion y proceso para la preparacion de una hormona monopegilatada terminalmente-n para una hormona para el crecimiento humano ref. 01449/1 SV2004001674A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42782302P 2002-11-20 2002-11-20

Publications (1)

Publication Number Publication Date
SV2004001674A true SV2004001674A (es) 2004-05-17

Family

ID=32825103

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2003001674A SV2004001674A (es) 2002-11-20 2003-11-20 Conjugacion y proceso para la preparacion de una hormona monopegilatada terminalmente-n para una hormona para el crecimiento humano ref. 01449/1

Country Status (9)

Country Link
US (1) US20040127417A1 (es)
AR (1) AR042103A1 (es)
GT (1) GT200300250A (es)
NL (3) NL1024831C2 (es)
PA (1) PA8588901A1 (es)
PE (1) PE20040797A1 (es)
SV (1) SV2004001674A (es)
TW (1) TWI281864B (es)
UY (1) UY28085A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
EA200500475A1 (ru) 2002-09-09 2005-10-27 Нектар Терапеутикс Ал, Корпорейшн Водорастворимые полимерные алканалы
AU2003263552A1 (en) * 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
CN102319437B (zh) * 2002-12-26 2017-10-13 山景医药公司 具有增强的生物学效用的干扰素‑β的聚合物缀合物
JP2006519170A (ja) * 2002-12-26 2006-08-24 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体
US20070105770A1 (en) * 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
BRPI0507436A (pt) * 2004-02-09 2007-07-03 Pharmacia Corp conjugados antagonistas de receptor do hormÈnio do crescimento humano quimicamente modificados
WO2006042847A2 (en) * 2004-10-18 2006-04-27 Novo Nordisk A/S Method for the preparation of oxime, thiazolidine, dithiane, dithiolane or hydrazone linked analogues of growth hormone
WO2006042848A2 (en) * 2004-10-18 2006-04-27 Novo Nordisk A/S Growth hormone conjugates
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US20060233740A1 (en) * 2005-03-23 2006-10-19 Bossard Mary J Conjugates of an hGH moiety and a polymer
CA2620638A1 (en) * 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
WO2007097934A2 (en) * 2006-02-17 2007-08-30 Elusys Therapeutics, Inc. Methods and compositions for using erythrocytes as carriers for delivery of drugs
US9175061B2 (en) * 2006-07-07 2015-11-03 Novo Nordisk Health Care Ag Protein conjugates and methods for their preparation
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
EP2157432A1 (en) * 2008-08-15 2010-02-24 Qiagen GmbH Method for analysing a complex sample by mass spectrometry
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP3355384A1 (en) * 2017-01-31 2018-08-01 Universite De Liege Flexible thin-films for battery electrodes
CN114539384B (zh) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US5618697A (en) * 1982-12-10 1997-04-08 Novo Nordisk A/S Process for preparing a desired protein
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DE68925966T2 (de) * 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
CA2230492C (en) * 1995-09-21 2009-05-26 Genentech, Inc. Human growth hormone variants
KR100731826B1 (ko) * 1999-01-14 2007-06-22 볼더 바이오테크놀로지 인코퍼레이티드 유리 시스테인 잔기를 함유하는 단백질의 제조 방법
SE9904502D0 (sv) * 1999-12-09 1999-12-09 Pharmacia & Upjohn Ab Production of peptides

Also Published As

Publication number Publication date
PA8588901A1 (es) 2005-02-04
NL1024831C2 (nl) 2005-04-28
NL1032282C2 (nl) 2007-03-09
GT200300250A (es) 2004-08-18
NL1028837A1 (nl) 2005-08-30
TWI281864B (en) 2007-06-01
UY28085A1 (es) 2004-07-30
NL1024831A1 (nl) 2004-05-26
PE20040797A1 (es) 2004-12-10
NL1028837C2 (nl) 2006-08-14
TW200418878A (en) 2004-10-01
AR042103A1 (es) 2005-06-08
NL1032282A1 (nl) 2006-11-07
US20040127417A1 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
SV2004001674A (es) Conjugacion y proceso para la preparacion de una hormona monopegilatada terminalmente-n para una hormona para el crecimiento humano ref. 01449/1
ATE312635T1 (de) Ventilanordnung
PA8539901A1 (es) Novedosa sal de succinato de o-desmetil-venlafaxina
PT777482E (pt) Composicao de combinacao para utilizacao em doencas imunologicas
SG160437A1 (en) Modified human growth hormone
DE60015112D1 (de) Peptidextrakt aus lupinen und pharmazeutische oder kosmetische oder pharmaco-nahrungsmittel zusammensetzung, die so ein extrakt enthalten
DE60101339D1 (de) Stimulierung des knochenwachstums mit peptidderivaten von thrombin
AU2003279838A1 (en) Prosthetic foot with resilient ankle and olbique attachment
CY1112439T1 (el) Μεταλλαγμα fsh-γλυκοζυλιωσης
AR023869A1 (es) Gonadotropinas
CO5611088A2 (es) Reduccion del crecimiento del vello
UY28154A1 (es) Composiciones y metodos de cuidado oral
NO20031860D0 (no) Kahalaolid F
DE69026269D1 (de) Bioadhäsive zusammensetzung und pflaster
ES2038969T3 (es) Procedimiento para la renaturalizacion de proteinas.
DE50210038D1 (de) Implantat mit oberflächenstruktur
ATA18952001A (de) Verwendung von selenithältigen präparaten zur topischen oder bukkalen anwendung
AR011697A1 (es) Composiciones farmaceuticas, uso de lamivudina en la manufactura de tales composiciones farmaceuticas.
ES2125354T3 (es) Composicion a base de tandospirona o de sus analogos.
BR0308795A (pt) Amidas do ácido sulfamico
BR0012006A (pt) Método para evitar inflamações, doenças autoimunes e crescimento de tumor, e, uso de substâncias que suprimem a ativação mediada por ltbr
ES2191206T3 (es) Nueva utilizacion de la creatina.
ES2148779T3 (es) Procedimiento para la fabricacion de una horma.
TW200503748A (en) Biologically active peptide comprising tyrosyl-seryl-valine (YSV)
MX9605402A (es) Nueva sustancia activa peptidica y su obtencion.

Legal Events

Date Code Title Description
FD Lapse